Antifungal agent 22

CAS: 2640054-39-1 F: C21H26Cl3NOS W: 446.86

Antifungal agent 22 (compound D16) is a potential and orally active antifungal agent for CM (cryptococcal meningitis), w

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Antifungal agent 22 (compound D16) is a potential and orally active antifungal agent for CM (cryptococcal meningitis), with an IC50 of 0.5 μg/mL. Antifungal agent 22 can penetrate the blood-brain barrier and kill the C. neoformans H99 cells by destroying the integrity of fungal cell membranes. Antifungal agent 22 shows selective anti-Cryptococcus activity with good metabolic stability and low cytotoxicity[1].
Target	IC50: 0.5 μg/mL (Fungal).
Invitro	Antifungal agent 22 (compound D16) (0-1 μg/mL, 24 h) inhibits ergosterol biosynthesis, which results in stress-induced upregulation of ERG genes in C. neoformans H99[1].Antifungal agent 22 (0-8 μg/mL) effectively inhibits the growth of C. neoformans H99 (0-72 h), inhibits the formation of C. neoformans H99 biofilms in a concentration-dependent manner (24 h)[1].Antifungal agent 22 (0-8 μg/mL, 48-72 h) shows selective anti-Cryptococcus activity, has a fungistatic effect[1].Antifungal agent 22 (0-100 μM, 48 h) shows low cytotoxicity against a human HUVEC cell line with an IC50 of 20.18 μM[1]. Cell Proliferation Assay Cell Line:
In Vivo	Antifungal agent 22 (D16) (15 mg/kg, Intragastrically, daily for 5 days) shows potent anti-Cryptococcal efficacy[1]. Animal Model:
Name	Antifungal agent 22
CAS	2640054-39-1
Formula	C21H26Cl3NOS
Molar Mass	446.86
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Li W, Yun Z, Ji C, et al. Discovery of Novel Sertraline Derivatives as Potent anti-Cryptococcus Agents.J Med Chem. 2022 Mar 6;10.1021/acs.jmedchem.1c01845.

SARS-CoV-2-IN-12